AUTHORS
Alberto Guijosa, MD, Nickolas Tsakmaklis2, Amanda Kofides, MSc3, Nick Paciaroni, PhD4, Stefano R. Bonissone, PhD5, Thiago Lima6, Natalie Castellana, PhD7, Richard Carson, PhD8, Hao Sun, MD, PhD9, Maria Luisa Guerrera, MD10, Tarek Mouhieddine, MD11, Camille Edwards, MD12, Andrew Branagan, MD, PhD13, Shayna Sarosiek, MD14, Jorge J Castillo, MD15, Zachary R Hunter, PhD16, Steven Treon, MD, PhD17
AFFILIATIONS
1 Brigham and Women's Hospital, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Binding Site, San Diego, California, United States
5 Abterra Biosciences, San Diego, California, United States
6 Abterra Biosciences, San Diego, California, United States
7 Abterra Biosciences, San Diego, California, United States
8 Abterra Biosciences, San Diego, California, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
13 Massachusetts General Hospital, Boston, United States
14 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
15 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
16 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
17 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
ABSTRACT
Introduction: Waldenström macroglobulinemia (WM) shows one of the strongest familial aggregations described for any malignancy, yet its biological basis remains poorly understood. Germline susceptibility loci (SNPs) at 6p (rs116446171) and 14q (rs117972357) were identified in an NIH collaborative study (Park et al, Blood 2024; 144 (S1): 4358), but how these variants contribute to familial disease remains undefined. Earlier serum protein electrophoresis and immunofixation (SPEP/IFX) suggested that multiclonality may be more common in IgM than IgG or IgA monoclonal gammopathies, raising the possibility that inherited susceptibility favors the emergence of multiple independent B-cell clones. Hypothesizing that familial WM is a multiclonal process, we aimed to uncover multiclonality using mass spectrometry (MS) and assess clonal origin at the genomic level.
Methods: We assessed 220 patients with IgM monoclonal gammopathies (212 WM and 8 IgM MGUS). Serum samples were analyzed by SPEP/IFX and intact light-chain MALDI-TOF MS (EXENT System, Thermo Fisher Scientific). Multiclonality was defined by MS as the presence of ≥2 distinct IgM mass peaks within the same sample. Germline DNA from CD19 depleted peripheral blood underwent PCR-based genotyping for the chromosome 14 susceptibility single-nucleotide polymorphism rs117410836 (SNP14).
In a matched subset, corresponding serum samples underwent de novo antibody peptide sequencing (Griffin, Abterra Biosciences) and concurrent CD19-selected bone marrow samples underwent immunoglobulin repertoire sequencing (clonoSEQ, Adaptive Biotechnologies; independent clonotypes defined as productive sequences present in >2% of cells), enabling direct comparison of serum monoclonal proteins to genetically independent marrow clones.
Results: Median age was 65 years, 61% were male, and 47/220 (21%) had a first-degree relative with WM (familial disease). MS detected multiclonality in 42/220 (19%): 31 biclonal, 6 triclonal, 4 tetraclonal, and 1 pentaclonal. SPEP/IFX established multiclonality in 8/220 (4%).
MS-defined multiclonality was markedly enriched in familial versus sporadic disease (42% vs 13%; p<0.001), a pattern also observed by conventional SPEP/IFX, although at a lower frequency (11% vs 1.7%; p=0.003). SNP14 was enriched in familial disease (46% vs 11%; p<0.001) and was independently associated with multiclonality (46% vs 13%; p<0.001), including among patients without a reported family history (37% vs 10%; p=0.001). Multiclonality prevalence rose progressively with germline burden, from 10% with neither factor to 33% with family history alone, 37% with SNP14 alone, and 55% with both (p<0.001). In multivariable analysis adjusting for age, sex, and prior therapy, family history (OR 4.6; p=0.004), SNP14 (OR 6.3; p=0.001), and their combination (OR 14.4; p<0.001) were each independently associated with multiclonality.
To establish that MS peaks reflect independent clones, we analyzed the CD19-selected bone marrow immunoglobulin repertoire of 12 untreated patients at a genetic level: 6 familial multiclonal cases matched 1:1 (for age, sex and marrow involvement percent) to 6 sporadic monoclonal controls. Two or more independent productive light-chain clonotypes were identified in the bone marrow of 4/6 familial cases versus 0/6 controls. Each clone carried a distinct rearrangement with different V genes or J genes, suggesting independent recombination rather than intraclonal diversification. De novo serum light-chain peptide sequencing, performed in 10/12 of these patients, identified two or more distinct sequences in all 5/5 familial multiclonal cases and a single sequence in all 5/5 sporadic controls. The predominant serum light-chain sequence matched the predicted CDR3 junction peptide of the most abundant productive marrow sequence in 9/10 patients.
Conclusions: Multiclonality Underlies Familial Waldenström Macroglobulinemia. A history of familial WM or inheritance of the SNP14 (rs117972357) germline susceptibility variant each conferred an approximately five- and six-fold higher likelihood of multiclonality, respectively, and increased to more than fourteenfold when both are present. Because familial aggregation is likely under-recognized in this indolent disease, multiclonality and the SNP14 germline variant may serve as surrogate markers of inherited susceptibility. Our findings provide novel insights for the etiology underlying familial WM disease.
DISCLOSURES
Alberto Guijosa, MD: No relevant conflicts of interest to declare.